Converging observations indicate that dysregulation of FGFR4 downstream signaling pathways, such as Wnt/β-catenin [9], JAK/STAT [10], and PI3K-AKT [11], leads to enhanced cell growth and metastatic potential in cancer progression. The gene discussed is FGFR4; the disease is cancer.